Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.

Medtronic’s investment is contingent on Anteris completing a proposed $200 million public stock offering.

A federal judge has paused the merger of the only two companies developing a heart device made for high-risk patients suffering from ...

Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.

The global TAVR embolic protection market is experiencing steady growth, with revenue estimated to increase from approximately $124 million in 2023 to around $403 million by 2032. This growth, driven ...

Since it went on the market, the newer device has been the subject of several reports of hemolysis. This would seem ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

PHOENIX — Abrazo Arizona Heart Hospital in Phoenix became the first health center in the state to use a new device that serves as an alternative to open-heart surgery this week. Cardiologist Timothy ...